Physician profile
Annette Eppler
NPI 1518199769
$10,400.58
in general payments reported to CMS, 2019-2025
22 companies · $1,938 in 2025
The $1,938 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,930 · 2022: $2,425 · 2023: $2,372 · 2024: $1,736 · 2025: $1,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,934 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,934.03 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,283.54 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $864.34 | 2021-2025 | Ajovy |
| Pfizer INC. | $787.89 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $581.84 | 2022 | |
| Lundbeck LLC | $360.61 | 2021-2025 | Vyepti |
| Lilly USA, LLC | $310.10 | 2021-2025 | Emgality, Reyvow |
| Amgen INC. | $303.68 | 2021-2023 | Aimovig |
| Scilex Pharmaceuticals INC. | $273.68 | 2023-2025 | Ztlido |
| Impel Pharmaceuticals INC. | $220.51 | 2023 | Trudhesa |
| Axsome Therapeutics, INC. | $208.02 | 2025 | Symbravo |
| Allergan, INC. | $180.02 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $176.97 | 2021-2023 | |
| Currax Pharmaceuticals LLC | $175.45 | 2021-2024 | Onzetra Xsail |
| Tonix Medicines, INC. | $157.83 | 2025 | Zembrace Symtouch |
| Biohaven Pharmaceuticals, INC. | $151.57 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $108.46 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $87.79 | 2022 | |
| Almatica Pharma LLC | $43.24 | 2021 | |
| Supernus Pharmaceuticals, INC. | $39.41 | 2021 | |
| Azurity Pharmaceuticals, INC. | $35.71 | 2025 | Horizant, Zonisade |
| Amneal Pharmaceuticals LLC | $30.53 | 2021-2022 | |
| Impel Pharmaceuticals LLC | $19.39 | 2025 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annette Eppler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.